TY - JOUR
T1 - Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine
AU - Hangalapura, Basav N.
AU - Oosterhoff, Dinja
AU - De Groot, Jan
AU - Boon, Louis
AU - Tuẗing, Thomas
AU - Van Den Eertwegh, Alfons J.
AU - Gerritsen, Winald R.
AU - Van Beusechem, Victor W.
AU - Pereboev, Alexander
AU - Curiel, David T.
AU - Scheper, Rik J.
AU - De Gruijl, Tanja D.
PY - 2011/9/1
Y1 - 2011/9/1
N2 - In situ delivery of tumor-associated antigen (TAA) genes into dendritic cells (DC) has great potential as a generally applicable tumor vaccination approach. Although adenoviruses (Ad) are an attractive vaccine vehicle in this regard, Ad-mediated transduction of DCs is hampered by the lack of expression of the Ad receptor CAR on the DC surface. DC activation also requires interaction of CD40 with its ligand CD40L to generate protective T-cell-mediated tumor immunity. Therefore, to create a strategy to target Ads to DCs in vivo, we constructed a bispecific adaptor molecule with the CAR ectodomain linked to the CD40L extracellular domain via a trimerization motif (CFm40L). By targeting Ad to CD40 with the use of CFm40L, we enhanced both transduction and maturation of cultured bone marrow-derived DCs. Moreover, we improved transduction efficiency of DCs in lymph node and splenic cell suspensions in vitro and in skin and vaccination site-draining lymph nodes in vivo. Furthermore, CD40 targeting improved the induction of specific CD8+ T cells along with therapeutic efficacy in a mouse model of melanoma. Taken together, our findings support the use of CD40-targeted Ad vectors encoding full-length TAA for in vivo targeting of DCs and high-efficacy induction of antitumor immunity.
AB - In situ delivery of tumor-associated antigen (TAA) genes into dendritic cells (DC) has great potential as a generally applicable tumor vaccination approach. Although adenoviruses (Ad) are an attractive vaccine vehicle in this regard, Ad-mediated transduction of DCs is hampered by the lack of expression of the Ad receptor CAR on the DC surface. DC activation also requires interaction of CD40 with its ligand CD40L to generate protective T-cell-mediated tumor immunity. Therefore, to create a strategy to target Ads to DCs in vivo, we constructed a bispecific adaptor molecule with the CAR ectodomain linked to the CD40L extracellular domain via a trimerization motif (CFm40L). By targeting Ad to CD40 with the use of CFm40L, we enhanced both transduction and maturation of cultured bone marrow-derived DCs. Moreover, we improved transduction efficiency of DCs in lymph node and splenic cell suspensions in vitro and in skin and vaccination site-draining lymph nodes in vivo. Furthermore, CD40 targeting improved the induction of specific CD8+ T cells along with therapeutic efficacy in a mouse model of melanoma. Taken together, our findings support the use of CD40-targeted Ad vectors encoding full-length TAA for in vivo targeting of DCs and high-efficacy induction of antitumor immunity.
UR - http://www.scopus.com/inward/record.url?scp=80052251198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052251198&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-11-0804
DO - 10.1158/0008-5472.CAN-11-0804
M3 - Article
C2 - 21747119
AN - SCOPUS:80052251198
SN - 0008-5472
VL - 71
SP - 5827
EP - 5837
JO - Cancer Research
JF - Cancer Research
IS - 17
ER -